BioArctic nominates Anna-Lena Engwall for election to its Board of Directors

– SWEDEN, Stockholm –  BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the nomination of Anna-Lena Engwall for her election to its Board of Directors as a new member at the next AGM on May 22, 2024.

The nomination committee proposes to nominate Eugen Steiner, Cecilia Edström, Pär Gellerfors, Lars Lannfelt, Lotta Ljungqvist, and Mikael Smedeby to be re-elected as board members, with Eugen Steiner re-elected as chairperson to.

Ivar Verner and Håkan Englund have requested not to be re-elected.

About Anna-Lena Engwall

Anna-Lena Engwall holds a degree in nursing from Karolinska Institutet and a degree in market economics from IHM Business School. She has more than 25 years of experience in the life science and pharmaceutical industry with leading roles in commercialization, marketing,g and business development and has during her career held several positions at AstraZeneca, Shir,e and Novartis. Her broad experience, industry knowledge,e, and significant network are expected to provide the board with additional valuable expertise. Anna-Lena Engwall has previously been a member of the board of directors of Life, Läkemedelsindustriförenings Service AB, and is independent of the Company, its management,t, and its major shareholders.

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma company focusing on innovative treatments that can delay or stop the progression of neurodegenerative diseases. The company invented Leqembi (lecanemab) – the world’s first drug proven to slow the progression of the disease and reduce cognitive impairment in early Alzheimer’s disease. Leqembi has been developed together with BioArctic’s partner Eisai, who are responsible for regulatory interactions and commercialization globally. In addition to Leqembi, BioArctic has a broad research portfolio with antibodies against Parkinson’s disease and ALS as well as additional projects against Alzheimer’s disease. Several of the projects utilize the company’s proprietary BrainTransporter technology, which has the potential to actively transport antibodies across the blood-brain barrier to enhance the efficacy of the treatment. BioArctic’s B share (BIOA B) is listed on the Nasdaq Stockholm Large Cap.


- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.